Grifols (GRFS) Competitors $8.12 -0.07 (-0.79%) As of 11:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. TEVA, SMMT, ITCI, GMAB, RDY, VTRS, MRNA, QGEN, ASND, and ROIVShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Viatris Moderna Qiagen Ascendis Pharma A/S Roivant Sciences Teva Pharmaceutical Industries (NYSE:TEVA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk. Does the MarketBeat Community believe in TEVA or GRFS? Teva Pharmaceutical Industries received 987 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 67.88% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.16% of users gave Grifols an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes133867.88% Underperform Votes63332.12% GrifolsOutperform Votes35156.16% Underperform Votes27443.84% Which has preferable earnings & valuation, TEVA or GRFS? Grifols has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.62B1.13-$1.64B-$1.15-14.41Grifols$7.21B0.78$64.20M$1.177.00 Do insiders and institutionals believe in TEVA or GRFS? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is TEVA or GRFS more profitable? Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Grifols' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% Grifols N/A N/A N/A Is TEVA or GRFS a better dividend stock? Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 6.1%. Grifols pays an annual dividend of $0.36 per share and has a dividend yield of 4.4%. Teva Pharmaceutical Industries pays out -87.9% of its earnings in the form of a dividend. Grifols pays out 30.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio. Which has more volatility & risk, TEVA or GRFS? Teva Pharmaceutical Industries has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Do analysts rate TEVA or GRFS? Teva Pharmaceutical Industries presently has a consensus price target of $24.43, indicating a potential upside of 47.38%. Given Teva Pharmaceutical Industries' higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Grifols 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media prefer TEVA or GRFS? In the previous week, Teva Pharmaceutical Industries had 29 more articles in the media than Grifols. MarketBeat recorded 34 mentions for Teva Pharmaceutical Industries and 5 mentions for Grifols. Grifols' average media sentiment score of 1.30 beat Teva Pharmaceutical Industries' score of 1.01 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 21 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTeva Pharmaceutical Industries beats Grifols on 14 of the 20 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.63B$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio7.008.9226.8419.71Price / Sales0.78253.80392.34117.39Price / Cash9.5465.8538.2534.62Price / Book0.656.466.794.50Net Income$64.20M$143.98M$3.23B$248.18M7 Day Performance4.33%2.03%1.53%0.20%1 Month Performance14.07%4.11%10.05%12.37%1 Year Performance13.91%-2.87%16.71%7.04% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.0009 of 5 stars$8.13-0.8%N/A+6.8%$5.59B$7.21B6.9526,300TEVATeva Pharmaceutical Industries3.2899 of 5 stars$17.92+5.8%$24.43+36.4%-0.1%$20.31B$16.62B-12.3636,800Positive NewsOptions VolumeSMMTSummit Therapeutics3.0294 of 5 stars$25.26+5.4%$37.40+48.1%+478.8%$18.76B$700,000.00-90.21110Positive NewsITCIIntra-Cellular Therapies0.868 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S3.4281 of 5 stars$19.93+2.9%$39.17+96.5%-29.6%$12.78B$21.64B11.451,660News CoverageHigh Trading VolumeRDYDr. Reddy's Laboratories2.329 of 5 stars$13.93+3.9%$17.00+22.1%+4.0%$11.62B$311.31B22.1724,800Positive NewsGap UpVTRSViatris2.0782 of 5 stars$8.96+2.2%$10.50+17.2%-22.6%$10.63B$14.33B-12.1137,000Trending NewsMRNAModerna4.5384 of 5 stars$25.70+6.0%$53.95+109.9%-82.0%$9.94B$3.14B-2.773,900Trending NewsGap UpQGENQiagen3.9909 of 5 stars$42.92+2.5%$48.42+12.8%-3.5%$9.54B$1.98B119.526,030Positive NewsASNDAscendis Pharma A/S3.3631 of 5 stars$154.43+2.1%$216.07+39.9%+28.7%$9.42B$368.70M-21.75640Positive NewsROIVRoivant Sciences2.1392 of 5 stars$10.99+3.3%$17.50+59.2%-2.8%$7.84B$122.59M-73.26860Positive NewsUpcoming Earnings Related Companies and Tools Related Companies TEVA Alternatives SMMT Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives VTRS Alternatives MRNA Alternatives QGEN Alternatives ASND Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRFS Stock Free GRFS Stock Alerts